binding TNF, one of the dominant inflammatory cytokines or regulatory proteins that play an important role in both normal immune function and the cascade of reactions that causes the inflammatory process of psoriatic arthritis and RA. The binding of ENBREL to TNF renders the bound TNF biologically inactive, resulting in significant reduction in inflammatory activity.
Individual results may vary. In medical studies, ENBREL worked for about two out of three adults with RA.
Since the product was first introduced, the following have been reported in patients using ENBREL:
Serious Infections
- Many occurred in people prone to infection, such as those with advanced or poorly controlled diabetes
- Some serious infections were fatal
- Rare cases of tuberculosis
What to do/Not do
- Do not start ENBREL if you have an infection or are allergic to ENBREL or its components
- Tell your doctor if you are prone to infection
- Stop ENBREL if a serious infection occurs
- Contact your doctor if you have questions about ENBREL or develop an infection
Serious nervous system disorders such as multiple sclerosis, seizures, or inflammation of the nerves of the eyes.
- Tell your doctor if you have ever had any of these disorders or if you develop them after starting ENBREL.
Rare reports of serious blood disorders (some fatal)
- Contact your doctor immediately if you develop symptoms such as persistent fever, bruising, bleeding, or paleness
The incidence of cancer has not increased with extended exposure to ENBREL and is similar to the expected rate.
ENBREL can also cause injection site reactions.
In a medical study of patients with JRA, infections, headaches, abdominal pain, vomiting, and nausea occurred more frequently than in adults.
- The kinds of infections reported were generally mild and simila
'"/>
Contact: Rebecca Hamm, Amgen
805-447-3872
Porter Novelli 20-Jun-2003Page: 1 2 3 4 Related biology news :1.
ENBREL provided rapid and significant relief for psoriasis patients in second pivotal study2.
ENBREL rapidly, significantly improved back pain, mobility, function in ankylosing spondylitis3.
ENBREL combo therapy inhibits joint damage progression, offers significant RA symptom relief4.
ENBREL is first therapy approved for psoriatic arthritis5.
New Phase 2 study shows ankylosing spondylitis patients respond to ENBREL (etanercept)6.
Phase 3 psoriatic arthritis data for ENBREL (etanercept) announced at a national scientific meeting7.
Rare mutations can significantly increase risk factor for heart disease8.
Cancer health risk significantly underestimated by EPAs ambient model estimates9.
Double mastectomies significantly lower risk of breast cancer in women who are genetically at risk10.
HAART therapy significantly prolongs survival in AIDS patients with central nervous system lymphoma11.
Cognitive abilities increase significantly with time in most prematurely born children